Meta-analysis of inhaled corticosteroids response in children with asthma. Source: International Congress 2019 – Paediatric asthma: risk factors, biomarkers and the basics Year: 2019
Asthma control and medication use five years after early or delayed introduction of inhaled corticosteroids in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004
Children with mild asthma: do they benefit from inhaled corticosteroids? Source: Eur Respir J 2002; 20: 1470-1475 Year: 2002
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Is GLCCI1 associated with response to inhaled corticosteroids in asthma patients? Source: Annual Congress 2012 - Gene-environment treatment and asthma Year: 2012
The oral corticosteroid sparing effect of omalizumab in patients with severe chronic asthma: Is there a difference when you become 12 years old? Source: Annual Congress 2011 - Treating childhood asthma Year: 2011
Quality of life of patients with asthma exacerbations treated with high doses of inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 114s Year: 2002
Estimate of asthma control and adherence to inhaled corticosteroids in children with asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Obesity and the response to inhaled budesonide in patients with asthma Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007
Predictors of adherence to inhaled corticosteroids in children with asthma and their parents in a multi-ethnic population Source: Annual Congress 2007 - Education, communication and quality of life in childhood asthma Year: 2007
Rescue-free days in patients with mild persistent asthma receiving montelukast sodium or an inhaled corticosteroid Source: Eur Respir J 2002; 20: Suppl. 38, 113s Year: 2002
Less than 20% of COPD patients persist with long-acting inhaled drugs for at least three years Source: Annual Congress 2009 - Drug effects in COPD Year: 2009
Suboptimal persistence with inhaled corticosteroid (ICS) mono-therapy among children with persistent asthma in the UK Source: Eur Respir J 2006; 28: Suppl. 50, 709s Year: 2006
Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015
Pharmacogenetics of inhaled corticosteroid response in adults with asthma Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020
Are inhaled corticosteroids increasing the “load” for some patients with COPD? Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017 Year: 2017
Airways diseases: influential developments in the past 5 years Source: Annual Congress 2005 - PG14 - Moving on from the Millennium: developing trends in respiratory medicine (jointly organised with ACCP) Year: 2005
The effect of single dose inhaled budesonide on Amppc20 in patients with mild asthma: a 3 month follow up Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005
Intermittent versus daily inhaled corticosteroids (ICS) in children and adults with mild persistent asthma: A Cochrane review Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012